Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of November 2022, with the report dated November 3, 2022. The filing serves to disclose a material event regarding the company's listing status on the Nasdaq Stock Market LLC.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of a corporate event rather than a financial statement.
Material Changes
On November 3, 2022, Evogene Ltd. announced the receipt of a letter from the Nasdaq Stock Market LLC. The specific contents of the letter are not detailed in the body of this filing but are referenced via an attached press release (Exhibit 99.1).
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the implication of the Nasdaq correspondence. The document incorporates the attached press release by reference for further details on the matter.
Key Facts for Investor Verification
- Verify the specific content of the letter received from Nasdaq Stock Market LLC by reviewing the attached press release (Exhibit 99.1).
- Confirm the current listing status of Evogene Ltd. on Nasdaq following this notification.
- Note that this filing does not include updated financial performance data for the period.